Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prime Medicine, Inc.PRME · Entity 5281 | Chief Scientific Officer | February 27, 2025 | March 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prime Medicine, Inc.
Report date February 27, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.42 · Expires 2035-02-27 | Direct | 275,000 |
Reported balance
After 2025-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-27 · Grant · Acquired 275,000 · Balance 275,000 F1: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2025 Filed Mar 3, 2025 20:15 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 275,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001894562-25-000008 · wk-form4_1741050933.xml · derivative · entry 1 Duffield Jeremy · CIK 0001922590 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:03 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 180,995 | $0.00 Strike: $8.49 | $0.00 |
DisclosureSEC source: 0001894562-24-000013 · wk-form4_1708725783.xml · derivative · entry 1 Duffield Jeremy · CIK 0001922590 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,995 Underlying: Common Stock · 180,995 shares Expires 2034-02-21 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 21, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:23 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 180,995 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001894562-23-000005 · wf-form4_168065417838934.xml · derivative · entry 1 Duffield Jeremy · CIK 0001922590 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,995 Underlying: Common Stock · 180,995 shares Expires 2033-03-31 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 31, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.